It's never fun when you see one of your holdings sell off ~20% or so in a single trading day. This typically means that something has gone terribly wrong and can really test an investor's intestinal fortitude. Thankfully, I don't invest in companies that experience this sort of volatility very often. The vast majority of my portfolio is made up of large cap, relatively conservative, well established companies with stable cash flows and long histories of reliable dividend growth. However, I have decided a small portion of my portfolio to more speculative, growth oriented names. This keeps me on my toes as an investor and adds a bit of octane to my portfolio's fuel with regard to long-term total returns. One of these non-dividend paying growth oriented companies that I own is Celgene (CELG). Unfortunately for me, this stock has sold off to the tune of 34% in the last couple of weeks since hitting 52 week highs in early October. Admittedly, the company has posted a couple of negative news items that have impacted the stock; however, I think this move from $147 down to $96 was simply too much, too fast. Because of this, I added to my CELG position at $96.03 on Thursday during its post-earnings sell-off.
Celgene: Sell-Off Is Overdone
10/27/17
Stories you Need to Know
- David Nevins Interviews Dr. Matthew Frieman, Associate Professor, University of Maryland School of Medicine
- Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
- Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
- Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results
- MTBC Reports Record Full Year 2020 Results
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
- Merck to Acquire Pandion Therapeutics
- Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights

